Clinical Trials
How To Select A CDMO: Focus On Client-Centered Approach
When it comes to the pharmaceutical sector, choosing the correct contract development and manufacturing organization (CDMO) is essential to having a successful trip through the...
Clinical Trials
FDA Approval of AMVUTTRA for ATTR Amyloidosis
Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics, has announced U.S. FDA approval of AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy associated with wild-type...
Clinical Trials
Rina-S Shows Promise in Advanced Ovarian Cancer
Genmab has reported encouraging findings from the Phase 2 RAINFOL-01 trial of rinatabart sesutecan (Rina-S®), an experimental folate receptor-alpha (FRα)-targeted, TOPO1 antibody-drug combination (ADC). Data...
Clinical Trials
Artificial Intelligence – Giving Clinical Trial A Facelift
Across the past so many years, there have been pharmaceutical companies that have been integrating artificial intelligence steadily into many elements of clinical development. The...
Clinical Trials
New Data Shows Gazyva’s Superiority in Lupus Nephritis
The New England Journal of Medicine has published detailed findings from Roche’s Phase III REGENCY trial, which demonstrated the superiority of Gazyva®/Gazyvaro® (obinutuzumab) in combination...
Clinical Trials
EYLEA HD® Phase 3 Trial Yields Promising Results
Regeneron Pharmaceuticals, Inc. announced promising results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema in patients...
Clinical Trials
Pfizer’s BRAFTOVI Improves Survival in Phase 3 Trial
Pfizer has announced groundbreaking results from the Phase 3 BREAKWATER trial, showcasing the effectiveness of its BRAFTOVI® (encorafenib) combination regimen in the treatment of metastatic...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.